Stefan Abele

This inventor holds 12 USPTO granted patents and 2 published patent applications, plus 7 CIPO patents and 12 EPO patents, primarily in Pyrimidine Synthesis. Top assignees: Actelion Pharmaceuticals Ltd, Idorsia Pharmaceuticals Ltd. Active years: 2012-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Stefan Abele. Retrieved from https://idiyas.com/inventor/stefan-abele

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 12 (Patent Applications = 2)

% Patents Active = 75.0

CIPO Patents = 7 (Patent Applications = 3)

EPO Patents = 12 (Patent Applications = 15)

Average Co-Inventor Count = 2.9

ph-index = 3

Forward Citations = 48(Granted Patents)

Location History:

Zurich, CH (2012)
Oberwil BL, CH (2014)
Allschwil, CH (2013 - 2021)

Company Filing History:

10 out of 217

Actelion Pharmaceuticals Ltd

patents

2 out of 81

Idorsia Pharmaceuticals Ltd

patents

Years Active: 2012-2021

Loading Chart...

Areas of Expertise:

Pyrimidine Derivatives

Naphthyridine

Bicyclo Compounds

Thiazolidin Derivatives

Synthesis Processes

Chemical Intermediates

Fluorinated Compounds

Diastereoselective Preparation

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10899695 - Process for the synthesis of 1-aryl-1-trifluoromethylcyclopropanes (2021-01-26),

2. 9938244 - Process for manufacturing pyrimidine sulfamide derivatives (2018-04-10),

3. 9676731 - Preparation of pyrimidine intermediates useful for the manufacture of macitentan (2017-06-13),

4. 9556125 - Process for preparing a pyrimidine intermediate (2017-01-31),

5. 9422249 - Preparation of pyrimidine intermediates useful for the manufacture of macitentan (2016-08-23),

6. 9296673 - Preparation of bicyclo[2.2.2]octan-2-one compounds (2016-03-29),

7. 9187476 - Process for manufacturing naphthyridine derivatives (2015-11-17),

8. 9127002 - Process for manufacturing a naphthyridine derivative (2015-09-08),

9. 8912340 - Process for the preparation of 2-imino-thiazolidin-4-one derivatives (2014-12-16),

10. 8816118 - Diastereoselective preparation of bicyclo[2.2.2]octan-2-one compounds (2014-08-26),

11. 8492555 - Salts of isobutyric acid (1 R*, 2R*, 4R*)-2-(2-{[3-(4,7-dimethoxy-1 H-benzoimidazol-2-yl)-methyl-amino}-ethyl)-5-phenyl-bicyclo[2.2.2]oct-5-en-2-yl ester (2013-07-23),

12. 8263780 - Process for the preparation of 2-imino-thiazolidin-4-one derivatives (2012-09-11),

Title: The Innovative Contributions of Stefan Abele

Introduction

Stefan Abele is a notable inventor based in Allschwil, Switzerland. He has made significant contributions to the field of pharmaceuticals, holding a total of 12 patents. His work primarily focuses on the synthesis of complex chemical compounds that serve as intermediates in drug development.

Latest Patents

Among his latest patents is a process for the synthesis of 1-aryl-1-trifluoromethylcyclopropanes. This invention relates to the manufacturing of these compounds, which are crucial for creating calcium T channel blockers, as described in WO 2015/186056. Another significant patent involves a process for manufacturing pyrimidine sulfamide derivatives. This invention details a method for producing a specific compound through a reaction involving various chemical components, highlighting Abele's expertise in organic chemistry.

Career Highlights

Stefan Abele has worked with prominent companies in the pharmaceutical industry, including Actelion Pharmaceuticals Ltd and Idorsia Pharmaceuticals Ltd. His experience in these organizations has allowed him to contribute to groundbreaking research and development in the field.

Collaborations

Throughout his career, Abele has collaborated with esteemed colleagues such as Jacques-Alexis Funel and Gunther Schmidt. These partnerships have further enhanced his innovative capabilities and have led to the successful development of various pharmaceutical processes.

Conclusion

Stefan Abele's contributions to the field of pharmaceuticals through his patents and collaborations demonstrate his commitment to innovation and excellence. His work continues to impact the industry positively, paving the way for future advancements.

Profile summary based on public USPTO records.